We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

20 hedge funds and large institutions have $2.14M invested in Cellectar Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.62% less ownership

Funds ownership: 11.04% → 10.42% (-0.62%)

35% less funds holding

Funds holding: 31 → 20 (-11)

54% less capital inflows, than outflows

Capital inflows: $134K | Capital outflows: $290K

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

85% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 13

Holders
20
Holders Change
-11
Holders Change %
-35.48%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
6
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$71.9K
2
1900 Wealth Management
1900 Wealth Management
Texas
+$57.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$5.03K

Top Sellers

Rank Fund Capital Flow
1
Maven Securities
Maven Securities
Jersey
-$71.9K
2
ACM
AIGH Capital Management
Maryland
-$44.4K
3
Northern Trust
Northern Trust
Illinois
-$39K
4
Citadel Advisors
Citadel Advisors
Florida
-$28K
5
Cozad Asset Management
Cozad Asset Management
Illinois
-$23K

CLRB Hedge Fund Activity: Q3 2022 in Review

20 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2022, worth a combined $2.14M — down 41% from $3.65M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CLRB and 2 opened new positions — a net loss of 11 holders — while 6 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $71.9K. The largest seller was Maven Securities, cutting an estimated $71.9K.

  • 20 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2022, down from 31 in Q2 2022.
  • Funds reported $2.14M of Cellectar Biosciences stock for Q3 2022, down 41% quarter-over-quarter.
  • 2 funds opened new Cellectar Biosciences positions in Q3 2022 and 13 closed out, a net change of -11 holders.
  • The largest Cellectar Biosciences buyer in Q3 2022 was Morgan Stanley, an estimated $71.9K added.
  • The largest Cellectar Biosciences seller in Q3 2022 was Maven Securities, an estimated $71.9K sold.

Based on aggregated 13F filings for Q3 2022.